A 12-year observational study which aimed to sequence the genome, exome, and RNA in tumors from patients with multiple myeloma was able to define distinct subtypes of the disease, according to an international team of scientists led by researchers from the Translational Genomics Research Institute, part of City of Hope.
Long-term results from the phase III CARTITUDE-4 study show a single infusion of Carvykti (ciltacabtagene autoleucel) significantly extended overall survival in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor, reducing the risk of death by 45% versus standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone.
